ArticleDiscover oncology2026
Integration of bulk and single-cell RNA-seq data identifies a cellular senescence-related prognostic signature in liver hepatocellular carcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Liver hepatocellular carcinoma (LIHC) is a heterogeneous malignancy with poor prognosis, but the landscape of cellular senescence-related genes (CSRGs) in LIHC remains incompletely characterized. Here, we curated 167 CSRGs and performed integrative bulk and single-cell RNA-seq analyses using TCGA, ICGC, and TISCH datasets. Fifteen prognostic CSRGs were identified and stratified LIHC patients into two distinct molecular subtypes: Cluster 2 exhibited an immune-excluded phenotype with poor prognosis, whereas Cluster 1 represented an immune-desert phenotype. A CSRGs-based risk score was constructed and validated as an independent prognostic factor across cohorts. Single-cell analysis identified EEF1E1 as a key CSRG predominantly expressed in malignant hepatocytes, correlating with advanced clinicopathological features and immune infiltration. Functional experiments demonstrated that EEF1E1 knockdown significantly suppressed LIHC cell migration and invasion. Collectively, this study establishes a robust CSRGs-based prognostic signature. It also identifies EEF1E1 as a functionally relevant gene with oncogenic potential and a potential therapeutic target in LIHC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.